EVEROLIMUS-ASSOCIATED ADVERSE EVENTS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER UPDATED RESULTS FROM BOLERO-2

被引：0
|
作者：
Campbell-Baird, Cynthia [1 ]
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
来源：
ONCOLOGY NURSING FORUM | 2013年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E428 / E428
页数：1
相关论文
共 50 条
  • [31] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Ito, Yoshinori
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Piccart-Gebhart, Martine J.
    Hortobagyi, Gabriel N.
    Rugo, Hope S.
    Gnant, Michael
    Campone, Mario
    Sahmoud, Tarek
    Pritchard, Kathleen I.
    Burris, Howard A.
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Shinzaburo Noguchi
    Norikazu Masuda
    Hiroji Iwata
    Hirofumi Mukai
    Jun Horiguchi
    Puttisak Puttawibul
    Vichien Srimuninnimit
    Yutaka Tokuda
    Katsumasa Kuroi
    Hirotaka Iwase
    Hideo Inaji
    Shozo Ohsumi
    Woo-Chul Noh
    Takahiro Nakayama
    Shinji Ohno
    Yoshiaki Rai
    Byeong-Woo Park
    Ashok Panneerselvam
    Mona El-Hashimy
    Tetiana Taran
    Tarek Sahmoud
    Yoshinori Ito
    [J]. Breast Cancer, 2014, 21 : 703 - 714
  • [33] Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
    Gnant, Michael
    Greil, Richard
    Hubalek, Michael
    Steger, Guenther
    [J]. BREAST CARE, 2013, 8 (04) : 293 - 299
  • [34] Everolimus beim metastasierten hormonrezeptorpositiven MammakarzinomEverolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    C. Richter-Ehrenstein
    [J]. Der Onkologe, 2012, 18 (5): : 435 - 437
  • [35] Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Ito, Yoshinori
    Rugo, Hope S.
    Dakhil, Shaker
    Hortobagyi, Gabriel N.
    Campone, Mario
    Csoszi, Tibor
    Baselga, Jose
    Puttawibul, Puttisak
    Piccart, Martine
    Heng, Daniel
    Noguchi, Shinzaburo
    Srimuninnimit, Vichien
    Bourgeois, Hugues
    Gonzalez Martin, Antonio
    Osborne, Karen
    Panneerselvam, Ashok
    Taran, Tetiana
    Sahmoud, Tarek
    Gnant, Michael
    [J]. CLINICAL BREAST CANCER, 2013, 13 (06) : 421 - U113
  • [36] BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.
    Rugo, Hope S.
    Campone, Mario
    Gnant, Michael
    Neven, Patrick
    Pistilli, Barbara
    Baselga, Jose
    Bauly, Hounayda
    Taran, Tanya
    Sahmoud, Tarek
    Hortobagyi, Gabriel N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [37] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    [J]. ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [38] Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2-advanced breast cancer
    Burris, H.
    Gnant, M.
    Hortobagyi, G.
    Hart, L.
    Yardley, D. A.
    Eakle, J.
    Provencher, L.
    Brechenmacher, T.
    Saletan, S.
    Taran, T.
    Rugo, H.
    [J]. CANCER RESEARCH, 2013, 73
  • [39] Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer
    Connolly, Roisin M.
    Stearns, Vered
    [J]. ONCOLOGY-NEW YORK, 2013, 27 (06): : 571 - +
  • [40] Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast Cancer: Preliminary results from BOLERO-2.
    Hortobagyi, Gabriel N.
    Piccart-Gebhart, Martine J.
    Rugo, Hope S.
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandro T.
    Deleu, Ines
    Shtivelband, Mikhail
    Provencher, Louise
    Masuda, Norikazu
    Dakhil, Shaker R.
    Anderson, Ian
    Chen, David
    Damask, Amy
    Huang, Alan
    McDonald, Robert
    Taran, Tanya
    Sahmoud, Tarek
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345